The role of zinc in renal pathological changes in diabetic status by Fernando, Julie & Zhou, Shaobo
Volume 5 • Issue 3 • 1000165
J Nutr Disorders Ther








nal Disorders & Therapy
ISSN: 2161-0509
Nutritional Disorders & Therapy
Fernando and Zhou, J Nutr Disorders Ther 2015, 5:3
http://dx.doi.org/10.4172/2161-0509.1000165
Research Article Open Access
*Corresponding author: Zhou S, Department of Life Science, Institute of 
Biological and Environmental Science and Technology (iBEST), Faculty of Creative 
Arts, Technologies and Science, University of Bedfordshire, Park Square, Luton, 
LU1 3JU, United Kingdom, Tel: +00441582743541; E-mail: sbzhou@yahoo.com
Received May 22, 2015; Accepted June 08, 2015; Published June 13, 2015
Citation: Fernando J, Zhou S (2015) The Role of Zinc in Renal Pathological 
Changes in Diabetic Status. J Nutr Disorders Ther 5: 165. doi:10.4172/2161- 
0509.1000165
Copyright: © 2015 Fernando J, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
The Role of Zinc in Renal Pathological Changes in Diabetic Status
Julie Fernando and Shaobo Zhou*
Department of Life Science, Institute of Biological and Environmental Science and Technology (iBEST), Faculty of Creative Arts, Technologies and Science, University of 
Bedfordshire, Park Square, Luton, LU1 3JU, United Kingdom
Keywords: Zinc; Diabetes mellitus; Oxidative stress; Chronic 
hyperglycaemia
Introduction
Currently, there are 382 million people with diabetes mellitus (DM). 
Almost 600 million people worldwide will suffer from this condition by 
2035 [1]. 
Hyperglycaemia, the main underlying symptom of DM, is caused 
by either a defect in insulin secretion and/or insulin action. Chronic 
hyperglycaemia and its defects in other related metabolic regulation may 
be associated with secondary damage in organ systems including the 
kidneys, eyes, nerves, and blood vessels [2].
There are two main types of diabetes, type 1 and 2 diabetes (T1D 
and T2D). Renal failure is second to myocardial infarction as a cause of 
death from DM. Three lesions are typically encountered in DM patients 
with renal disease, including glomerular lesions, renal vascular lesions, 
and necrotizing papillitis [3]. The most important glomerular lesions are 
capillary basement membrane thickening. Excessive glomerulosclerosis 
can produce adequate levels of ischemia to the kidneys that can develop 
into end-stage renal disease, requiring dialysis or renal transplantation [3]. 
Increased DM prevalence rates, predominantly in developing 
countries, follow the trend of lifestyle changes and certain diets. One 
particular area in research is zinc (Zn). The sufficient availability of this 
transition metal has shown to be essential for biological processes [4] 
including optimal nucleic acid and protein metabolism as well as cell 
growth, division, and function [5].
Interestingly, some studies have shown DM patients had increased 
levels of Zn excretion in urine compared to non-DM controls [6] and that 
DM patients are usually Zn deficient.
This has encouraged further research into the possible positive effects 
of Zn supplementation on DM patients. Several studies have shown its 
beneficial effects on renal pathological changes in T1D and T2D subjects 
by reducing oxidative stress, glomerular damage, lymphocytic infiltration, 
and urinary albumin excretion. 
As DM incident rates increase rapidly worldwide, and the UK 
health service is predicted to spend 16.9 billion pounds on DM-related 
complications over the next 25 years, there is pressure to find treatment 
for this condition. Therefore, this particular study includes analysis of 
published findings and have found promising results that show Zn 
reducing, and in some cases completely preventing renal damage. 
The intention of this paper is to highlight the significance of Zn 
and encourage further research in this area, and its potential use as a 
treatment against renal pathological symptoms in DM patients. 
Diagnosis of DM 
Blood glucose level tests are the common methods of diagnosis 
for DM, which include fasting glucose concentration test, post-
standard carbohydrate load, and oral glucose tolerance test (OGTT). 
Patients with abnormally high levels of glucose in any of these tests are 
considered to have impaired glucose tolerance and recognised as pre-
diabetics or diabetics. 
Another diagnostic test is to measure levels of glycated haemoglobin 
(HbA1c), which identifies the average plasma glucose concentration 
over a long period of time, for a period of two to three months. High 
levels of HbA1c are usually seen in DM patients and individuals 
with renal failure. HbA1c is formed when haemoglobin binds to 
plasma glucose. Due to high numbers of glucose molecules binding 
to haemoglobin in DM patients, high levels of HbA1c is typically 
expected. Together with the fasting plasma glucose test, the HbA1c test 
is mainly used to diagnose T2D.
Main Types of DM and its Mechanisms 
There are two main types of diabetes, T1D and T2D. Most patients 
depend on exogenous insulin for survival. Without insulin they 
develop severe metabolic complications such as ketoacidosis and coma. 
Although the clinical onset of T1D is abrupt, this disease results from 
chronic autoimmune attack on β-cells that usually begins several years 
before the disease becomes evident. The common symptoms of the 
disease such as hyperglycaemia and ketosis appear late in its course, 
after more than 90% of β-cells have been destroyed. 
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T2D is caused by a combination of peripheral resistance to 
insulin activity and inadequate insulin secretion by pancreatic β-cells 
that precedes hyperglycaemia and is typically accompanied by β-cell 
hyperfunction and hyperinsulinemia in early stages of DM [3]. 
T2D is a complex multifactorial disease where both genetic [7-9] 
and environmental factors [10-12] play a role. Environmental factors 
such as lifestyle and dietary habits, and also genetic factors are involved 
in the pathogenesis as evidenced by the greater concordance rate of 
the disease in monozygotic twins (35% to 60%) compared to dizygotic 
twins [13,14]. 
Other types of DM fall into monogenic and secondary causes. 
Although the major types of DM arise by different pathogenic 
mechanisms, the long-term complications in kidneys, eyes, nerves, and 
blood vessels are the same and are the principal causes of morbidity 
and death. DM includes a group of metabolic disorders caused by the 
disruption of glucose reabsorption in kidney tubules.
Glucose homeostasis and the process of filtration and 
reabsorption of glucose in the kidney 
In diabetic circumstances, hyperglycaemia causes filtration of large 
numbers of glucose molecules from blood plasma to the Bowman’s 
capsule. High concentration of glucose in urine leads to saturation 
of transport proteins in the epithelium, restricting glucose molecules 
from leaving the kidney tubules. Urine containing high glucose solute 
(glycosuria) causes osmotic diuresis, increasing the volume of urine 
excreted out of the body (polyuria). 
Normal glucose homeostasis is regulated by three interrelated 
processes including the production of glucose in the liver, glucose 
uptake and utilization by peripheral tissues, and actions of insulin 
and other regulatory hormones such as glucagon. Insufficient levels of 
insulin in the body, which occurs in DM, can cause accumulation of 
glucose in cells and lead to cell damage, including in renal cells.
As glomerulosclerosis progresses in DM patients with nephrotic 
syndrome, symptoms such as proteinuria, hypoalbuminemia, and 
oedema become evident. Excessive glomerulosclerosis can produce 
adequate levels of ischemia to the kidneys that can be seen as granular 
lesions on its surface [15]. 
Zinc in the Human Body 
Zn is a trace element found in microorganisms, plants, and 
animals. Although trace quantities are contained within organisms, the 
presence of this transition metal has shown to be essential for biological 
processes [4]. Approximately 300 enzymes and more proteins contain 
Zn components, which emphasizes its essential role for human health. 
Optimal nucleic acid and protein metabolism, as well as cell growth, 
division, and function require sufficient availability of Zn [5].
In the human body, most Zn is found in the muscle and bone 
and smaller concentrations are found in some organs including the 
liver, gastrointestinal tract, and kidney. Oral ingestion of Zn leads 
to its absorption through the small intestine and then its release into 
blood serum where it can be absorbed into different areas of the body 
and ultimately excreted by binding to proteins such as albumin and 
transferrin [16]. 
Cellular Zn involves efficient homeostatic control that avoids 
accumulation of excess Zn [17] and redistributes Zn to avoid its 
deficiency in specific organs e.g. brain [18]. Cellular Zn homeostasis 
is mediated by two protein families; the Zn-importer (Zip, Zrt, Irt-
like proteins) family containing 14 proteins that transport Zn into the 
cytosol, and the Zn transporter (ZnT) family, comprising 10 proteins 
transporting Zn out of the cytosol [19]. Regulation of homeostasis is 
crucial to maintain cellular viability and prevent deregulation, which 
can lead to damage of the cell and ultimately cell death. 
Cellular Zn homeostasis is mediated by three main mechanisms 
(Figure 1). One is the transportation of Zn into the cytosol through 
the plasma membrane by importers from the Zip-family, and it is 
exported out of the cytosol by proteins from the ZnT-family. Another 
is due to Zn-binding proteins such as metallothionein (MT) that 
maintain Zn homeostasis. To enable Zn re-distribution, it needs to be 
mobilized from its tight binding sites by coordinating Zn to sulphur 
donors. This allows direct Zn transfer and redox reactions to occur 
to the redox-inert Zn ion. The final main mechanism is transporter-
mediated sequestration of Zn into intracellular organelles, including 
endoplasmic reticulum, Golgi, and lysosomes.
Intracellular Zn homeostasis is maintained by the MT/thionein-
system, where free Zn ions bind to apo-protein thionein (Tred) to 
form MT (Figure 1). Elevated levels of free Zn ions can bind to Zn 
finger structures of the metal-regulatory transcription factor (MTF)-1, 
inducing the expression of Tred. Oxidation of thiols by reactive oxygen 
(ROS) or nitrogen (RNS) species triggers the formation of the oxidized 
protein thionin (Tox), which generates Zn signals and reduces oxidant 
signals, thereby reducing oxidative stress [20] (Figure 1). 
MTs have been widely recognised in their involvement with Zn 
Figure 1: Cellular Zn homeostasis and its impact on cytotoxicity and during 
Zn deficiency. (A) Cellular Zn homeostasis. Zn is transported into the cytosol 
by Zip-family and exported out by ZnT-family. Zn-binding proteins (e.g. MT) 
maintain Zn homeostasis. It coordinates Zn to sulphur donors, allowing Zn 
transfer and redox reactions to occur. (B) Intracellular Zn homeostasis by the 
MT/thionein-system [20].
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homeostasis. Overall, MT has a variety of functions including the 
regulation of apoptosis and more relevantly, the maintenance of Zn 
homeostasis. Due to the unique structural characteristics of MT, it 
can bind up to seven Zn ions. A study on the effects of MT on tubular 
epithelial cells in the kidney showed the up-regulation of MT stimulated 
the hypoxia-inducible factor and hypoxia-responsive elements (HIF-
HRE) pathway, which stabilizes protein expression in cells and reduces 
renal injury caused by hypoxia [21].
Decreased levels of Zn in the body can cause damaging effects 
towards growth, neuronal development, and immunity. There are 
several causes of Zn deficiency including insufficient dietary intake 
e.g. diet with lower Zn content, malabsorption e.g. acrodermatitis 
enteropathica, increased excretion e.g. chronic renal disease [22,23], 
and increased Zn loss e.g. sickle cell disease [24].
Zinc and Diabetes
In 1934, Zn was discovered as a component of insulin crystals 
therefore suggested the importance of Zn to maintain normal biological 
processes in the body. The deregulation of Zn homeostasis can lead to 
Zn deficiency or excess Zn in the body, which can affect the formation 
of insulin crystals that may lead to insufficient levels of insulin and 
result in DM. 
Possible components that may be involved in Zn deregulation 
include defects in MT as this protein is predominantly involved in 
Zn homeostasis. Alternatively it could be caused by defects in the Zn 
transporter protein ZnT-8, which delivers Zn ion from the cytoplasm 
into insulin granules [25-27]. 
As well as being a significant component of insulin, Zn also relates 
to DM in the sense that studies on animal DM models and human have 
shown increase levels of Zn excretion in urine compared to non-DM 
controls [6]. This indicates that DM patients are usually Zn deficient. 
The definite cause for this is yet unknown, however a number of studies 
have indicated a positive correlation between increased zincuria with 
polyuria, since osmotic diuresis is one of the symptoms of DM [28-
30]. Therefore high levels of Zn are excreted in urine, resulting in Zn 
deficiency in the body. Also hyperzincuria has been linked with blood 
glucose concentration, glycosuria and proteinuria [29,31,32]. 
Improvements in control diabetic glycaemic level after zinc 
supplementation
The relationship between Zn deficiency and DM has been the 
subject of many studies, some using animal models [33-35] and some 
human subjects [36,37]. Diabetic subjects are commonly tested for 
blood glucose levels due to inadequate levels of insulin produced by 
the pancreas. A study on T1D rats (by STZ administration) showed 
lower blood glucose levels and 24-hour urinary protein levels after 3 
months of Zn supplication in DM subjects (Blood glucose level 15.84 
± 1.38 mmol/L, 24 h urine proteins 42.28 ± 15.15 mg) compared to 
DM rats without Zn supplementation (Blood glucose level 18.03 ± 1.72 
mmol/L, 24h urine proteins 59.25 ± 11.31 mg) [38]. This suggested that 
Zn might be involved in preventing hyperglycaemia and proteinuria, 
which are common symptoms of DM-induced renal damage. 
Studies have also shown the reduction of HbA1c in T2D patients 
after Zn supplementation [39-42]. A study on T2D patients suffering 
from microalbuminuria showed that HbA1c was significantly reduced 
from 8.0 ± 1.4% before treatment, to 7.2 ± 1.4% after 3 months of 
Zn supplementation [41]. Another paper studied the effects of Zn 
supplementation on 101 T2D patients and the level of glycaemic 
control. Group 1, which included 50 patients, were given Zn, and 51 
patients in Group 2 were given a placebo. Results showed a positive 
correlation between serum Zn levels and Zn intake. Also after 3 months 
of Zn supplementation, HbA1c% concentration decreased significantly 
while no significant changes were found in the control group. This 
indicates the beneficial effects of Zn supplementation in T2D as it 
elevated patients’ serum Zn levels and improved their glycaemic control; 
shown by the reduction in HbA1c% concentration [40]. Results from 
another study showed patients given Zn supplementation in addition 
to multivitamins improved glycaemic control by significantly reducing 
HbA1C% levels and fasting and postprandial glucose compared to 
patients receiving multivitamin only and placebo [42]. 
Improvements in diabetic glomerular function after zinc 
supplementation
The effects of a mixture of vitamins and minerals, including Zn 
have also shown improvements in glomerular function in T2D patients. 
Factors that significantly reduced are urinary albumin excretion (UAE) 
levels, fasting serum glucose and malondialdehyde concentrations. 
Malondialdehyde is a common marker for oxidative stress [43]. 
Several studies have investigated the effects of Zn supplementation 
on microalbuminuria in DM patients [41,44-46]. Results from studies 
show a significant decrease in UAE in subjects given Zn, whereas subjects 
not given Zn exhibited consistent high UAE levels [41]. This study has 
shown the renal-protective effects of Zn by significantly reducing UAE 
after Zn supplementation, which suggests reduced permeability of 
renal glomerulus to albumin in patients supplied with Zn. This also 
demonstrates the effectiveness of Zn as these improvements were seen 
within only 3 months, therefore shows the potential of Zn to possibly 
prevent renal damage at a relatively fast rate. However, the limitations 
of this study include only measuring fasting plasma glucose and not 
postprandial plasma glucose concentration. Hence these levels may 
change after Zn supplementation and alter the results. 
Further, another study on the effects of Zn on T2D patients with 
micro-albuminuria showed a significant decrease in homocysteine 
levels in the group supplemented with 30 mg/d of Zn for 3 months, 
whilst the group receiving the placebo showed no significant changes. 
Also high homocysteine concentrations in plasma are associated with 
glomerular filtration impairment [45]. Hence a decrease in this amino 
acid after Zn supplementation shows promising results.
In addition to research on damaged renal tubules, other substances 
involved in renal damage have been studied. For example, renal tissues 
from Zn-deficient DM rats that were given Zn supplementation 
showed a reduction in levels of connective tissue growth factor 
(CTGF). This particular matricellular protein is critically involved 
in fibrosis and renal damage as it acts as a downstream mediator of 
transforming growth factor-beta (TGF-β1)-induced fibrosis [47-49]. A 
number of studies have shown a positive correlation between the level 
of renal CTGF mRNA expression and glomerulosclerosis in diabetic 
mice [47,48,50,51]. The effects of Zn supplementation on reducing 
CTGF levels were seen in a study that examined CTGF levels in human 
renal proximal tubular (HK-11) cells, which showed inhibited CTGF 
expression in pre-treated HK-11 cells with Zn compared to cells not 
treated with Zn [38]. This suggests that Zn supplementation had a 
positive effect on these renal cells by reducing the levels of this protein, 
which may prevent TGF-β1 induced fibrosis and therefore reduce 
pathological changes in renal tissues.
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Inhibition of diabetic oxidative stress after zinc 
supplementation
A study on the antioxidant effects of Zn on T2D showed initial 
increases in oxidative stress, which was measured according to the 
presence of plasma thiobarbituric acid reactive substances (TBARS), in 
T2D patients compared to healthy patients (3.32 +/- 0.05 micro mol/L 
vs. 2.08 +/- 0.04 micro mol/L). After six months of Zn supplementation, 
T2D patients showed a significant reduction in plasma TBARS, in 
contrast to the placebo group where no significant changes were seen 
[52]. Another similar study also showed the potential antioxidant 
effects of Zn, although when combined with chromium. Plasma 
TBARS reduced more significantly in patients receiving Zn, Cr or a 
mixture of Zn and Cr supplementation [Cr (13.6%), Zn (13.6%) and 
Zn/Cr (18.2%)] [53]. However a study on T2D male patients showed 
Zn supplementation does not decrease oxidative stress in patients with 
normal Zn levels [54].
Hyperglycaemia has been found to be a risk factor of causing 
oxidative stress in DM [55]. Therefore, the relationship between 
hyperglycaemia and its possible effects on MT is an interesting area to 
focus on, since MT is involved in the counteraction of oxidative stress. 
As Zn is related to the expression of MT, the relationship between Zn 
supplementation and levels of MT expression in cells have been studied 
in HK-11 cells using RT-PCR methods [38]. Results showed that pre-
treatment of HK-11 cells with Zn induced MT expression. However, 
the study only used a single concentration of Zn (dissolved ZnSO4 
in tap water) and did not examine the effects of different doses of Zn 
supplementation, which may alter MT expression. Also, the study 
focused on tubular cells, so the effects on other types of renal tissue 
may differ. 
However, another study on 2 months old MT-KO (MT-I and MT-
II Knock Out) mice showed no significant differences in the molecular 
biomarkers, protein kinase B (Akt1 and Akt2), hexokinase II (HK2), 
and glycogen synthase kinase- 3beta (GSK-3β) expression between 
MT-KO mice with and without Zn supplementation [56]. Results also 
showed that Akt1, Akt2, HK2, and GSK-3β expression were increased 
in mice with MT expression after Zn supplementation. These results 
show that MT is required for Zn treatment to be therapeutically effective 
for renal protection, and also MT stimulates the phosphorylation of 
Akt and GSK-3 and increases HK2 expression. The reason for this is 
unknown however researches of this study assumed that without MT 
there would be limited Zn chaperones to release Zn to target molecules, 
which is required to stimulate Akt and GSK-3 phosphorylation and 
HK2 expression [57].
Improvements in diabetic glucose metabolism after zinc 
supplementation
Akt1 and Akt2 genes are recognised for their role in the regulation 
of glucose uptake by mediating insulin-induced translocation of 
the SLC2A4/GLUT4 glucose transporter to the cell surface [58]. It 
also regulates cell survival by inactivating components of apoptosis 
machinery. GSK-3β is an important molecule in renal glucose 
metabolism as it is involved in the conversion of glucose to glycogen, 
and provides a preventative effect on pathogenic fibrosis of the kidney 
[59]. 
HK2 is a glycolytic enzyme that phosphorylates glucose to produce 
glucose-6-phosphate, the first step in most glucose metabolism 
pathways. Expression of the HK2 gene is insulin-responsive, and 
studies have shown its involvement in the increased rate of glycolysis 
[60,61]. It is also known to regulate cytoprotection and apoptosis based 
on the metabolic state of the cell [62]. 
Studies have shown that Zn may play a similar role to that of 
insulin, causing it to stimulate Akt phosphorylation and activate 
glucose metabolism [63-65] and a recent study on podocytes showed 
the protective effects of Akt2 against damage induced by chronic kidney 
disease [66]. Therefore the importance of Akt2 for glucose metabolism 
led to the assumption that the protective effect of Zn was dependent 
on this enzyme. However, the study on 2-month old Akt2-KO diabetic 
mice showed increases in Akt, p-GSK-3β, and HK2 expression, even 
when the Akt2 gene was absent. Therefore implying that the deletion 
of Akt2 gene does not affect basal Akt phosphorylation, basal and 
contraction-stimulated GSK-3β phosphorylation, glycogen synthase 
phosphorylation or activity [67]. 
Further studies on Akt-mediated molecules have shown a link 
between renal pathological damage at the last stages of DM with 
decreased levels of Akt function in the kidneys [68-70]. A study 
on 3-month old T1D OVE26 mice showed abnormalities such as 
significantly decreased phosphorylation of Akt and GSK-3β, decreased 
expression of HK2, and increased expression of the Akt negative 
regulators phosphatase and tensin homolog (PTEN), protein-tyrosine 
phosphatase 1B (PTP1B), and tribbles homolog 3 (TRB3) [56]. All of 
these were significantly prevented after Zn supplementation.
Inhibiting the negative regulators of Akt suggests that cells may be 
able to regulate glucose levels and improve intracellular conditions due 
to Akt availability. This may also lead to the reduction in hyperglycaemia 
and excess glucose in renal tissues.
Improvement of diabetic renal pathology after zinc 
supplementation 
Most studies investigating the effects of a substance in renal 
tissues usually carry out histological examinations to visually detect 
any changes in comparison to controls [71-73]. A particular study 
on 3-month old T1D OVE26 mice showed after Zn supplementation, 
segmental glomerulosclerosis and extracellular matrix significantly 
decreased [56]. DM mice given saline showed excessive accumulation 
of extracellular matrix, which caused glomerular enlargement 
(Figure 2A). In addition, Sirius red staining showed excess collagen 
accumulation in DM mice but not in DM mice given Zn (Figure 2B). 
Therefore these results reveal an improvement in pathological changes 
after DM mice were treated with Zn (Figure 2). 
Along with histological examinations, semi-quantitative analysis 
can provide information on the state of the renal tissues. For example, 
the level of fibrosis in renal tissues can be measured by semi-
quantitative analysis of mesangial index, tubulointerstitial damage, 
and GBM thickness. A study on renal cells in T1D rats showed fewer 
pathological changes of the glomeruli, renal tubules, and interstitium 
in DM subjects given Zn supplements compared to DM subjects 
given a placebo [38]. Levels of mesangial index, tubulointerstitial 
damage, and GBM thickness were lower in DM/Zn subjects, therefore 
displayed fewer renal damage (Figure 3). This suggests that Zn may 
play a protective role against cellular injury in renal tissues in addition 
to renal fibrosis, which is one of the pathological changes seen in DM.
Protective effects of zinc supplementation on diabetic aorta 
oxidative damage
As well as investigating the beneficial effects of Zn supplementation 
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on renal organs, a study investigated the pathological effects of Zn 
supplementation in the aorta [74]. Results showed decreases in 
4-hydroxynonenal (4-HNE) and neurotrophin-3 (3-NT) expression 
in tissues of T1D OVE26 mice with Zn supplementation compared to 
DM subjects without Zn supplementation. This provides important 
information on the state of the tissues, as these factors are involved 
in oxidant-induced cell signalling and apoptosis. Therefore higher 
quantities are usually found during oxidative stress. 
The reduction in the expression of these factors as well as others 
(e.g. nuclear factor-like 2 transcription factor [74]) in DM subjects 
given Zn suggests that Zn supplementation decreases oxidative stress, 
and therefore reduces DM-induced oxidative damage in aortic tissue.
This provides valuable information that could be applied to 
renal blood vessels since renal atherosclerosis and arteriolosclerosis 
constitute part of the macrovascular disease seen in DM. Therefore 
this result may indicate that besides having beneficial effects on kidney 
cells, Zn supplementation could also have protective effects on renal 
blood vessels. 
Discussion
In summary, a large number of studies have shown the beneficial 
effects of Zn supplementation in a range of renal components including 
glycaemic control, glomerular function, and oxidative stress. 
When levels of insulin secretion are abnormal or sensitivity to 
insulin is reduced, glycaemic levels (either fasting or postprandial 
glucose levels) are not controlled, which develops into DM. Prolonged 
DM causes Zn homeostasis disorders, which is shown by the reduction 
of serum Zn [41]. This could be due to a restricted diet, decreased 
intestinal Zn absorption, or increased zincuria. The mechanism of 
renal disease complications involves the development of glycaemic 
disorder, oxidative stress, and pathological changes of the glomerulus 
(e.g. glomerulosclerosis). 
This paper showed the beneficial effects of Zn on various mechanisms 
of renal disease, including glucose transportation. This could be 
because increased amounts of Zn are transferred into pancreatic cells 
via increased Zn-T8 activities that also improves glucose transporter 
activity (e.g. SLC2 A4/GUT4) or Akt2 that increase glucose uptake. 
Hence this may improve insulin activity. Also Zn supplementation 
showed improvements to glycolysis by increased activity of HK2 (in 
the presence of MT), a key enzyme for the conversion of glucose into 
glucose-6-phosphate. 
A number of papers also presented reductions in oxidative stress 
after Zn supplementation, which could be caused by improvements 
in MT and Copper-Zn-Superoxide dismutase (SOD) activities that 
reduce oxidative stress biomarkers, TBARS and malondialdehyde.
Subjects that presented high CTGF levels (involved in fibrosis and 
renal damage) showed formation of glomerulosclerosis. However after 
Zn supplementation, increased GSK-3β activity was seen, which may 
have inhibited that process and reduce fibrosis.
Histological examinations displayed the decrease in collagen 
accumulation after Zn supplementation (Figure 2B) and this also 
reduced excessive accumulation of extracellular matrix.
Further, Zn supplementation improved 4-HNE and 3-NT factors 
as well as others (e.g. nuclear factor-like 2 transcription factor) in DM 
subjects. These factors are involved in oxidant-induced cell signalling 
and apoptosis. This suggests that Zn supplementation decreases 
oxidative stress, and therefore reduces DM-induced oxidative damage.
The extent to which these have improved is significant, especially 
when taking into account the time period of the studies. Some of the 
studies have shown considerable visible improvements to renal damage 
within three months. This could have long-term improvements for DM 
patients and possibly prevent end-stage renal disease, as well as reducing 
the number of patients needing renal dialysis and transplantation. 
This study has outlined substances that have only recently been 
associated with DM and/or Zn, such as MT and Akt2. Further research 
on the effects of Zn on MT in renal disease may lead to future treatments 
Figure 2: Histological examination of kidney tissues from 3-month old T1D 
OVE26 mice given saline or Zn supplementation. (A) Haematoxylin and 
eosin stain. Arrow showing accumulation of extracellular matrix, causing 
glomerular enlargement. (B) Sirius red stain. Arrow showing excess collagen 
accumulation [56].
Figure 3: Semi-quantitative analysis of mesangial index, tubulointerstitial 
damage, and GBM thickness in T1D rats. Tissue examinations show damage 
in DM as thick GBM is clearly visible compared to DM/Zn tissue [38].
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relating MT and Zn supplementation. Likewise, additional knowledge 
on Akt2 and the effects of Zn on other Akt isoforms such as Akt1 and 
Akt3 would be relevant to finding treatments for DM. Therefore this 
needs to be studied in the future. In addition, the improvements in 
micro-albuminuria and levels of protein excreted in urine after Zn 
supplementation described in this study could lead to further research 
on the mechanism of Zn on reducing permeability of renal glomerulus 
to albumin and other proteins.
The majority of studies analysed in this paper, included research 
studies on animal models than human subjects. However in particular 
instances where human models are used, several studies showed similar 
beneficial effects of Zn as in the animal studies. Specifically, a study 
investigating the effects of Zn on micro-albuminuria in T2D patients 
showed a decrease in UAE as serum Zn increases, which is similar to 
that of many animal studies [41]. 
More research is required on Zn supplementation and its 
pathological effects on animal models to increase knowledge about 
suitable cellular environments needed for Zn to have its beneficial 
effects in renal tissues. This would provide vital information about the 
possible side effects of Zn supplementation and whether it is safe to use 
as a long-term treatment for DM patients. Further research on human 
subjects is crucial for this. 
Studies on animal models were performed around the age of two to 
three months, and most of these studies show similar results to studies 
on human subjects over the age of 20 years, indicating that age may 
not be a contributing factor to the effects of Zn on renal pathological 
changes.
The effects of Zn supplementation on aortic damage were briefly 
discussed in this paper to see whether there are similarities between 
vascular tissues in the heart and in renal organs. Many studies showed 
positive effects after Zn supplementation. However there were also a 
small number not showing significant changes. For example, a study 
on forty males with T2D showed no significant differences with the 
baseline in the biomarkers F2- Isoprostanes (IsoPs) and allantoin in 
patients receiving Zn or the placebo [54]. IsoPs are involved in free 
radical peroxidation and have been used in a number of studies as 
a marker of oxidant injury in vivo [75-77]. Allantoin is a product of 
oxidation of uric acid by purine catabolism and has been used in clinical 
laboratories as a determination of oxidative stress in humans. Therefore 
unchanged levels of allantoin and IsoPs suggest Zn supplementation 
had no beneficial effects on oxidative stress.
Many previous studies have shown the positive effects of Zn, so 
this study provides important information that Zn supplementation 
may not have beneficial effects in certain situations. However, this 
study did not measure levels of Zn co-transporters in addition to Zn 
levels, and these are important factors to consider, as they are involved 
in the regulation of β-cell insulin processing and excretion. Therefore, 
variations in levels of co-transporters may have prevented Zn from 
having any effects. In addition, DM patients with low Zn levels were not 
used in this study and only males were included. Zn supplementation 
may have different effects on diabetic females with suboptimal or 
optimal Zn levels, which is frequently seen in DM patients. Also, the 
duration of this study was only 4 months so increasing the length of 
this study might produce different results. 
Conclusion
To conclude, all research articles mentioned in this study provides 
vital information about the relationship between Zn and DM because 
Zn deficiency is commonly seen in DM patients as a result of elevated 
urinary Zn excretion, decreased intestinal Zn absorption, and 
restricted diet. Therefore these findings emphasize the importance of 
regularly monitoring Zn levels in diabetic patients. The majority of 
studies aforementioned have demonstrated the beneficial effects of Zn 
supplementation on renal pathology of both T1D and T2D subjects. 
Despite this, there are some studies that have had limited impact on 
renal tissues after the administration of Zn. Therefore, the aim of this 
paper is to encourage further research in this area to consider Zn as a 
potential treatment against long-term renal damage in diabetic patients, 
which would decrease DM mortality rates due to renal damage, and 
reduce costs by national health services.
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